News & Press

Filter by year:

The EIB and GeNeuro sign a EUR 25 million credit line backed by InvestEU to support clinical developments against long-COVID

Geneva, Switzerland, March 7, 2023 – 07:30 CET - GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19, (PASC, post-COVID or Long-COVID), announced today the signature of a credit agreement for a total amount of up to EUR 25 million with the European Investment Bank ("EIB"), supported by the InvestEU programme.


Results 1-1 of 1